Abstract
Background Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.
Objective This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through February 25, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).
Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and February 25, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.
Results We included 483,928 hospitalizations of 449,124 unique patients who tested positive for a respiratory virus between October 01, 2019 and February 25, 2024.
Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout February 2024 (-20.0%) compared to January 2024. While the main contributors COVID- and influenza-associated hospitalizations decreased (-26.5% and - 22.7%), all other respiratory viruses increased, with HMPV increasing quickly (117.2%). For infants and children, the overall and individual rate of hospitalization decreased. Rhinovirus-associated hospitalizations account for the largest percentage of hospitalizations with 1.2% in the last week of February 2024. The population over 65 years of age also saw an overall decrease in respiratory virus-associated hospitalizations (-19.9%) like the overall population. However, HMPV-associated hospitalizations increased rapidly (+204.6%).
Discussion We continue to see evidence that respiratory virus-associated hospitalizations peaked at end of 2023 and continue to decrease overall, including for the two high-risk populations we studied. In February 2024, rhinovirus-associated hospitalizations were the main respiratory virus contributing to hospitalizations for infants and children, while COVID-associated hospitalizations were the largest contributor for the older adult population. However, HMPV-associated hospitalization rose quickly in the older adult population, and we will continue to monitor its trends in the upcoming month.
Overall populationOverall, the rate of hospitalizations associated with respiratory viruses decreased throughout February 2024 (20.0% decrease since end of January 2024). This is due to the decrease in COVID-(-26.5%) and influenza-associated hospitalizations (-22.7%). Hospitalizations for all other monitored respiratory viruses increased, including those associated with HPMV, which more than doubled (+117.2%) throughout the month. COVID- and influenza-associated hospitalizations make up 2.3% and 1.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of February 2024, respiratory virus-associated hospitalizations accounted for 4.0% of all hospitalizations.
Infants and children (age 0-4)For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout February (-28.4%). For individual viruses, associated hospitalizations decreased when counts were above reporting thresholds. In the last week of February, 2.8% of all hospitalizations in this age group were associated with a respiratory virus, and rhinovirus-associated hospitalizations were the largest individual contributor (1.2%).
Older adults (age 65 and over)In the population over 65 years of age, there was a 19.9% decrease in hospitalizations associated with respiratory viruses. COVID-, influenza-, and RSV-associated hospitalizations all continued to decrease throughout the month, while HPMV-, parainfluenza-, and rhinovirus-associated hospitalizations all increased. HMPV-associated hospitalizations increased by 204.6% compared to the last week of January. In the last week of February, 5.2% of all hospitalizations in this age group were associated with a respiratory virus.
Introduction
COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death, especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.
Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions, such as chronic lung diseases and asthma.
Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).
It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.
This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.
Methods
Data
We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and February 25, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on March 14, 2024 and included de-identified patient care data primarily located across ten states: Texas, New York, Florida, California, Michigan, Washington, Illinois, North Carolina, Louisiana, and Wisconsin.
Population
We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.
Hospitalization rate analysis
Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).
Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.
Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.
Results
Overall population
Our study population consists of 483,928 hospitalizations of 449,124 unique patients (Table 1).
Hospitalization rate over time
The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.
Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019
Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019
COVID-19
Our COVID study population consists of 352,142 hospitalizations of 338,646 unique patients (Table 2).
Hospitalization rate over time
The rate of COVID-associated hospitalization is shown in Figure 3. Figure 4 shows seasonal trends.
Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019
Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by s
Influenza
Our influenza study population consists of 42,789 hospitalizations of 38,271 unique patients (Table 3).
Hospitalization rate over time
The rate of influenza-associated hospitalization is shown in Figure 5. Figure 6 shows seasonal trends.
Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019
Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season
Human metapneumovirus (HMPV)
Our HMPV study population consists of 9,642 hospitalizations of 8,142 unique patients (Table 4).
Hospitalization rate over time
The rate of HMPV-associated hospitalization is shown in Figure 7. Figure 8 shows seasonal trends.
Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019
Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season
Parainfluenza virus
Our parainfluenza virus study population consists of 9,286 hospitalizations of 7,595 unique patients (Table 5).
Hospitalization rate over time
The rate of parainfluenza virus-associated hospitalization is shown in Figure 9. Figure 10 shows seasonal trends.
Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions since October 201
Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions by season
Respiratory syncytial virus (RSV)
Our RSV study population consists of 27,462 hospitalizations of 21,770 unique patients (Table 6).
Hospitalization rate over time
The rate of RSV-associated hospitalization is shown in Figure 11. Figure 12 shows seasonal trends.
Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019
Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season
Rhinovirus
Our rhinovirus study population consists of 42,607 hospitalizations of 34,700 unique patients (Table 7).
Hospitalization rate over time
The rate of rhinovirus-associated hospitalization is shown in Figure 13. Figure 14 shows seasonal trends.
Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019
Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season
Infants and children (age 0-4)
Our infants and children study population consists of 35,268 hospitalizations of 28,276 unique patients (Table 8).
Hospitalization rate over time
The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 15. Figure 16 shows the same data stacked to represent the combined impact of the viruses.
Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five
Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five
Older adults (age 65 and over)
Our older adults study population consists of 242,265 hospitalizations of 225,996 unique patients (Table 9).
Hospitalization rate over time
The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in Figure 17. Figure 18 shows the same data stacked to represent the combined impact of the viruses.
Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older
Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older
Discussion and Conclusion
Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout February 2024 (20.0% decrease since end of January 2024). This is due the decrease in COVID-(-26.5%) and influenza-associated hospitalizations (-22.7%).
Hospitalizations for all other monitored respiratory viruses increased, including those associated with HPMV, which more than doubled (+117.2%) throughout the month.
COVID- and influenza-associated hospitalizations make up 2.3% and 1.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of February 2024, respiratory virus-associated hospitalizations accounted for 4.0% of all hospitalizations.
For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout February (-28.4%). For individual viruses, associated hospitalizations decreased when counts were above reporting thresholds. In the last week of February, 2.8% of all hospitalizations in this age group were associated with a respiratory virus, and rhinovirus-associated hospitalizations were the largest individual contributor (1.2%).
In the population over 65 years of age, there was a 19.9% decrease in hospitalizations associated with respiratory viruses. COVID-, influenza-, and RSV-associated hospitalizations all continued to decrease throughout the month, while HPMV-, parainfluenza-, and rhinovirus-associated hospitalizations all increased. HMPV-associated hospitalizations increased by 204.6% compared to the last week of January. In the last week of February, 5.2% of all hospitalizations in this age group were associated with a respiratory virus.
Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed March 14, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual’s electronic health record or that it was excluded from the data to protect an individual’s identity as a part of Truveta’s commitment to privacy (Truveta, 2024).
We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.
Footnotes
We included updated data till end of February 2024.
